New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 23, 2014
14:03 EDTADXSAdvaxis treatment of osteosarcoma designated for orphan status
The company's live attenuated bioengineered Listeria monocytogenes immunotherapy was designated for orphan status as an osteosarcoma treatment, according to a post to the FDA's website. Reference Link
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 22, 2015
11:52 EDTADXSAdvaxis management to meet with Jefferies
Meeting to be held in New York on April 28 hosted by Jefferies.
April 21, 2015
13:01 EDTADXSAdvaxis presents Lm-LLO cancer immunotherapy data at AACR meeting
Advaxis announced the data of one clinical and two preclinical studies highlighting the survival outcomes and anti-tumor effects of its proprietary Lm-LLO cancer immunotherapy technology at the American Association for Cancer Research Annual Meeting 2015, held April 18 22 in Philadelphia, Pennsylvania. On Tuesday, April 21, Samir Khleif, M.D., Director of the State of Georgia Cancer Center, Georgia Regents University Cancer Center, presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies. The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively. On Monday, April 20, Nicola J. Mason, BVetMed, Ph.D., DACVIM, Assistant Professor of Medicine, University of Pennsylvania's School of Veterinary Medicine, presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal. Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period. Five of the treated dogs remain alive, with a median survival, to date, of all 10 study dogs reported at 285 days, which compares favorably to historical median survival time of 136 days in dogs treated with palliative radiation only.
April 20, 2015
07:20 EDTADXSAmerican Association for Cancer Research to hold annual meeting
Subscribe for More Information
April 17, 2015
17:03 EDTADXSAdvaxis files to sell $200M of common stock
April 13, 2015
08:43 EDTADXSAdvaxis price target raised to $25 from $14 at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use